Nucleus-targeted Silencer nanoplatform regulating ZEB1-AS1 in head and neck squamous cell carcinoma therapy
Haojie Yang, Yangfan Zhang, Zicong Tan, Zihao Liu, Yingzhe Yan, Qin Li, Phei Er Saw, Ning Liufu, Fengtao Ji · 2024
Read Nucleus-targeted Silencer nanoplatform regulating ZEB1-AS1 in head and neck squamous cell carcinoma therapy by Haojie Yang, Yangfan Zhang, Zicong Tan, Zihao Liu, Yingzhe Yan, Qin Li, Phei Er Saw, Ning Liufu, Fengtao Ji (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11585530.txt.
Description
Haojie Yang and co-authors silence a cancer-driving long RNA with a nucleus-targeted nanoparticle in head and neck cancer. Their 2024 study first flags the RNA, ZEB1-AS1, as overactive in tumor data, where high levels track poor outlook. Lab work ties it to spread and drug resistance.
Lowering the RNA slows the spread program in a cancer cell line and restores sensitivity to a standard drug; raising it does the reverse. The RNA acts through its partner gene and an opioid receptor downstream. A nanoparticle built to reach the nucleus ferries a mix of antisense and silencing strands, cutting the target in cells and animals. A three-marker model predicts patient outlook from the same pathway. The authors pitch RNA silencing as a live therapy route.
Catalog record
| CREATOR | Haojie Yang, Yangfan Zhang, Zicong Tan, Zihao Liu, Yingzhe Yan, Qin Li, Phei Er Saw, Ning Liufu, Fengtao Ji |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |